IRIS
AGUSTONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.498
AS - Asia 1.384
EU - Europa 852
SA - Sud America 218
AF - Africa 83
OC - Oceania 1
Totale 4.036
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.425
SG - Singapore 451
CN - Cina 373
HK - Hong Kong 213
IT - Italia 179
RU - Federazione Russa 178
VN - Vietnam 166
BR - Brasile 151
DE - Germania 119
FR - Francia 81
FI - Finlandia 73
GB - Regno Unito 66
ZA - Sudafrica 57
IN - India 46
CA - Canada 39
IE - Irlanda 38
BD - Bangladesh 32
MX - Messico 23
NL - Olanda 23
AR - Argentina 21
PL - Polonia 20
JP - Giappone 15
TR - Turchia 15
ES - Italia 14
IQ - Iraq 14
AT - Austria 13
VE - Venezuela 13
CZ - Repubblica Ceca 10
SE - Svezia 10
SA - Arabia Saudita 8
CO - Colombia 7
EC - Ecuador 7
MA - Marocco 7
PH - Filippine 7
UA - Ucraina 7
PK - Pakistan 6
BE - Belgio 5
CL - Cile 5
PY - Paraguay 5
DZ - Algeria 4
ID - Indonesia 4
JO - Giordania 4
KE - Kenya 4
KG - Kirghizistan 4
LT - Lituania 4
MY - Malesia 4
TN - Tunisia 4
UY - Uruguay 4
AZ - Azerbaigian 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
EG - Egitto 3
LV - Lettonia 3
AE - Emirati Arabi Uniti 2
CH - Svizzera 2
ET - Etiopia 2
JM - Giamaica 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
RW - Ruanda 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
YE - Yemen 1
Totale 4.036
Salva come PNG Salva come JPEG
Città #
San Jose 261
Singapore 232
Hong Kong 211
Ashburn 189
Dallas 178
Beijing 105
Council Bluffs 77
Boardman 67
Lauterbourg 58
Los Angeles 52
Munich 52
Ho Chi Minh City 50
Johannesburg 47
New York 47
Hanoi 46
Shanghai 41
Dublin 37
Redondo Beach 37
Turku 37
Helsinki 36
Moscow 36
Milan 32
Pavia 19
São Paulo 19
Santa Clara 18
Warsaw 18
Buffalo 16
Falkenstein 16
Frankfurt am Main 16
London 15
Tokyo 15
Düsseldorf 14
Orem 14
Chennai 13
Montreal 13
The Dalles 12
Toronto 12
Brooklyn 11
Guangzhou 11
Rome 11
Seattle 11
Boston 10
Phoenix 10
Stockholm 10
Manchester 9
Mexico City 9
Nuremberg 9
Chicago 8
Columbus 8
Atlanta 7
Baghdad 7
Brno 7
Cesena 7
Da Nang 7
Dhaka 7
Hyderabad 7
Palermo 7
Amsterdam 6
Ankara 6
Bắc Ninh 6
Denver 6
Elk Grove Village 6
Hải Dương 6
Querétaro 6
Fortaleza 5
Haiphong 5
Houston 5
Poplar 5
Rio de Janeiro 5
Tianjin 5
Vancouver 5
Vienna 5
Amman 4
Bishkek 4
Bondo 4
Changsha 4
Nairobi 4
San Francisco 4
Washington 4
Wuhan 4
Agadir 3
Asunción 3
Belo Horizonte 3
Buenos Aires 3
Cagliari 3
Charlotte 3
Desio 3
Durban 3
Florence 3
Istanbul 3
Jacksonville 3
Jeddah 3
Joinville 3
Ludhiana 3
Maastricht 3
Maracaibo 3
Mumbai 3
New Delhi 3
Quito 3
Riga 3
Totale 2.505
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 148
Smoking Habit and Respiratory Function Predict Patients' Outcome after Surgery for Lung Cancer, Irrespective of Histotype and Disease Stage 130
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 118
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 109
Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI 109
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study 104
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study 102
Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center "Blue Sky Radiomics" study on stage III unresectable NSCLC 101
Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience 98
Correlation between PD-L1 Expression of Non-Small Cell Lung Cancer and Data from IVIM-DWI Acquired during Magnetic Resonance of the Thorax: Preliminary Results 98
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets 93
Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study 91
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer 91
Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach 91
From Interconnection between Genes and Microenvironment to Novel Immunotherapeutic Approaches in Upper Gastro-Intestinal Cancers-A Multidisciplinary Perspective 90
CT Scan-Guided Fine Needle Aspiration Cytology for Lung Cancer Diagnosis through the COVID-19 Pandemic: What We Have Learned 88
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 82
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC) 79
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer 79
Phase I Clinical Trial on Pleural Mesothelioma Using Neoadjuvant Local Administration of Paclitaxel-Loaded Mesenchymal Stromal Cells (PACLIMES Trial): Study Rationale and Design 74
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 68
The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs 68
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC 67
Radiomics features as predictive and prognostic biomarkers in NSCLC 66
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry 66
Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy? 65
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling 65
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 64
Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features 64
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease 61
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis 60
Impact of hyponatremia in a tertiary cancer center: a one-year-survey at National Cancer Institute of Milan 59
Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review 57
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program 57
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines 57
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 57
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 57
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era 56
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer 56
The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma 55
The Clinical Value of Nutritional Care before and during Active Cancer Treatment 54
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group 53
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 53
T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma 51
A non-small cell lung cancer fragile elderly patient treated with immunotherapy and non-ablative radiation therapy: a case report of a winning combination 49
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer 46
Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial 45
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach 43
Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact 41
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients 41
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy 39
Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer? Analysis of a Phase II Trial 38
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 36
Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story 34
PACIFIC trial: new perspectives for immunotherapy in lung cancer 34
Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? 34
Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies 33
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations 32
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 30
Palonosetron Plus 1-Day Dexamethasone for the Prevention of Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy: Effect of Established Risk Factors on Treatment Outcome in a Phase III Trial 29
Palonosetron Plus Dexamethasone in Highly Emetogenic Chemotherapy: Pooled Data from Two Phase III Trials 28
Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders 24
Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem 21
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy 21
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment 2
Totale 4.111
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.363
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.363
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 8 0 1 3 31 0 79 15
2023/2024343 40 46 29 27 31 69 31 15 0 18 6 31
2024/20251.096 40 45 33 22 11 123 54 62 260 84 121 241
2025/20262.535 203 149 241 315 310 103 377 137 264 193 172 71
Totale 4.111